Journal Article10.1055/a-2055-4635
Nephroprotektion
01 Sep 2023
TL;DR: SGLT-2-Inhibitoren können die Progression einer chronischen Nierenerkrankung verringern, insbesondere bei Diabetes und Albuminurie.
read more
Abstract:
Die zu besprechende Studie hat zum Thema, dass sogenannte Natrium-Glukose-Kotransporter-2-Inhibitoren (SGLT-2-Inhibitoren) in anderen Studien die Progression einer chronischen Nierenerkrankung verlangsamt hatten, ohne dass dies primär Ziel der Untersuchungen war. Dies war insbesondere für Patienten mit Diabetes und Albuminurie festgestellt worden.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
References
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
22 Sep 2022
TL;DR: In this paper , Dapagliflozin was shown to reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure with ejection fraction of 40% or less.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Scott D. Solomon,John J.V. McMurray,Brian Claggett,W. De Boer,David L. DeMets,Adrian F. Hernandez,Silvio E. Inzucchi,Mikhail Kosiborod,Carolyn S.P. Lam,Felipe Martinez,Akshay S. Desai,Pardeep S. Jhund,Jan Bělohlávek,Chern-En Chiang,C. Jan Willem Borleffs,Josep Comín-Colet,Dan Dobreanu,Jarosław Drożdż,James C. Fang,Marco Antonio Alcocer-Gamba,Waleed Al Habeeb,Yaling Han,Jose Walter Cabrera Honorio,Stefan Janssens,Tzvetana Katova,Masafumi Kitakaze,Béla Merkely,Eileen O'Meara,José Francisco Kerr Saraiva,S. N. Tereshchenko,Jorge Thierer,Muthiah Vaduganathan,Orly Vardeny,Subodh Verma,Vinh N. Pham,Ulrica Wilderäng,Natalia Zaozerska,Erasmus Bachus,Dan Lindholm,Magnus Petersson,Anna Maria Langkilde +40 more
TL;DR: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction and results were similar in prespecified subgroups, including patients with or without diabetes.
771
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
01 Nov 2022
TL;DR: A systematic review and meta-analysis of SGLT2 inhibitor trials was conducted in this article , where the main outcomes were kidney disease progression (standardised to a definition of a sustained ≥50% decrease in estimated glomerular filtration rate [eGFR] from randomisation, a sustained low eGFR, end-stage kidney disease, or death from kidney failure), acute kidney injury, and a composite of cardiovascular death or hospitalisation for heart failure.
524